Abstract. Many attempts to demonstrate the oncogenic role of the JC virus (JCV) have been partially successful in producing brain tumors, either by direct inoculation of JCV into the brain or in transgenic models in rodents. We previously reported the presence of JCV DNA with a relatively high incidence in pulmonary and digestive organs. However, we could not prove the oncogenic role of JCV. We prepared a transgene composed of the K19 promoter, specific to bronchial epithelium with the JCV T-antigen and established transgenic (TG) mice. Pulmonary tumors were detected without any metastasis in 2 out of 15 (13.3%) 16-month-old K19/JCV T-antigen TG mice. Using immunohistochemistry (IHC), these tumors showed JCV T-antigen, p53 and CK 19 expression, but not expression of nuclear and cytoplasmic β-catenin and insulin receptor substrate 1 (IRS1). IHC revealed the same expression pattern as in the bronchial epithelium of the TG mice. One tumor, which was examined with laser capture microdissection and molecular biological tools, demonstrated an EGFR mutation but not a K-ras mutation. We propose that the pulmonary tumors were derived from the JCV T-antigen in a TG mouse model. These findings shed light on pulmonary carcinogenesis.

Introduction

JC virus (JCV), a member of the polyomavirus genus, which also includes SV40 and BK viruses, is a non-enveloped, 5,130-bp double-stranded DNA virus that forms minichromosomes with cellular histones (1). The JCV early region encodes 2 oncoproteins, large T-antigen (T-Ag) and small t antigen (t-Ag). The late region encodes 3 capsid proteins, VP1, VP2 and VP3, and a small regulatory protein, agnoprotein (2). The early viral proteins have high transformation and oncogenic potential in experimental systems (3). There are 2 possible outcomes of JCV infection. One possible outcome is the support of viral DNA replication by permissive cells, such as oligodendrocytes, resulting in a lytic infection. Another possibility is silent or abortive infection that may be linked to cell transformation in nonpermissive cells, such as those of the pulmonary and digestive epithelium (4).

As JCV has been frequently detected in tumors of the human central nervous system (CNS) (5), it has been suggested that this virus may have a possible association with a variety of human CNS tumors. However, the mechanisms involved in JCV-associated oncogenesis must be clarified since studies provide contradictory evidence as to whether or not JCV plays a causative role in human CNS tumors (6). Laghi et al (7), followed by Enam et al (8), were the first to report the presence of JCV DNA in colorectal cancers. We evaluated the presence of JCV DNA in Japanese patients with colorectal (9), gastric (10), oral (11) and lung cancer (12). While JCV DNA was detected in cancers of these organs, we could not demonstrate an association between the presence of JCV DNA and its oncogenic role.

Approximately 4 decades have passed since the first report that JCV is found in brain tumors following inoculation of this virus into the brain of newborn hamsters (13). Subsequently, several studies have shown that brain tumors arise in JCV transgenic mouse models (14,15). It is well-known that the JCV receptor is the 5-HT2A serotonin receptor, which is primarily restricted to glial cells (16). Therefore, it may be reasonable to conclude that JCV has a strong tendency to form neurotropic tumors (6). However, since JCV DNA has been shown to be present in pulmonary and digestive organs, we speculate that JCV may infect these organs through an unknown receptor. We created transgenic (TG) mice with a transgene including the K-19 promoter, which is specific to bronchial and digestive epithelium (17) and the JCV T-antigen. We found pulmonary tumors in 2/15 mice (13.3%) with no tumors in any other organs.

Materials and methods

Establishment and generation of K-19/JCV T-antigen transgenic mice. TG mice were generated using a 3.2-kb BalI/NcoI
restriction fragment from the plasmid pBJC, containing the K-19 promoter (a kind gift from Professor H. Oshima, Kanazawa University Cancer Research Institute) and the coding region for the viral early genes, large T- and small t-antigens. The DNA was microinjected into the pronucleus of fertilized mouse oocytes generated by the mating of C57BL/6J mice (Chrysalis DNX, Princeton, NJ, USA). Founder animals were mated with C57BL/6J mice, and all mice were screened for the presence of the transgene by DNA extraction from the tail tissue and real-time PCR analysis with primers specific to the transgene. Real-time quantitative PCR was performed using the SYBR® Premix DimerEraser (Takara Bio, Inc., Ohtsu, Japan) kit and LightCycler® (Roche Applied Science, Indianapolis, IN, USA). The primer set (5'TGGACATGTGTTGGCCCTC-3' and 5'TTTGGGCAATGCGAATGCTGT-3') was designed to detect JCV T-antigen DNA (amplicon size 168 bp), and reaction mixtures were prepared according to the manufacturer's protocol. After amplification, using hemizygous and wild-type mice (C57BL/6J), we generated standard curves. The homozygous, hemizygous and non-TG states in the target DNA samples were clearly distinguished by the difference in these C values. Potentially homozygous animals were validated by test breeding with wild-type partners. Pure JCV T-antigen+ mice were achieved after 3 generations.

In the present study, 15 TG mice (8 males and 7 females) and 10 control mice (5 males and 5 females) were euthanized by CO₂ inhalation at 16 months of age and were autopsied systemically.

Histologic and immunohistochemical (IHC) analyses of TG mice. Tissues from the lung, heart, liver, pancreas, spleen, kidney, esophagus, stomach, small intestine, large intestine and brain were obtained from TG and C57BL/6J control mice. Tissues from the lung, heart, liver, pancreas, spleen, kidney, esophagus, stomach, small intestine, large intestine and brain were obtained from TG and C57BL/6J control mice and fixed in 10% formalin. Histological examination was carried out by 3 pathologists (A.N., Y.M. and Y.T.). The IHC procedure was similar to that described previously (12). Primary antibodies were directed against JCV T-antigen (1:100 dilution, Pab416, mouse mAb; EMD Millipore, Darmstadt, Germany), p53 (1:50, Pab122, mouse mAb; Enzo Life Science, Farmingdale, NY, USA), β-catenin (1:1,000, rabbit pAb; Cell Signaling Technology, Inc., Beverly, MA, USA), IRS-1 (1:50, sc-8038, mouse mAb; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), cytokeratin CK-19 (1:100, rabbit mAb; Epitomics, Burlingame, CA, USA), CK-7 (1:100, KRT7, rabbit pAb; Proteintech Group, Chicago, IL, USA), CK-20 (1:50, mouse mAb; GeneTex, San Antonio, TX, USA), CD3 (1:100, goat pAb, Santa Cruz Biotechnology, Inc.), CD4 (1:50, mouse mAb; EMD Millipore), CD5 (1:50, mouse mAb; Abnova, Taipei, Taiwan), CD8 (1:50, rabbit mAb; GeneTex), CXCD20 (1:50, rabbit mAb; EMD Millipore), CD21 (1:50, mouse mAb; Santa Cruz Biotechnology, Inc.) and CD79a (1:100, rabbit pAb; LifeSpan Biosciences, Seattle, WA, USA).

Mutation analysis of K-ras and epidermal growth factor receptor. DNA samples from tumor lesions and bronchial epithelium were selectively captured from 10 μm dewaxed sections using a laser capture microdissection (LCM) system (LM200, Olympus, Tokyo). Isolation of DNA from LCM specimens was performed with a PicoPure® DNA Extraction kit (Arcturus Engineering, Mountain View, CA, USA) according to the manufacturer's protocol. The primers used for detection of codon 12 mutations were described elsewhere (18). The primers used for detection of epidermal growth factor receptor (EGFR) exon 18-21 mutations were 18A:2467-2446, 5'-ATACATGTGCAAAATGCTCCC-3' and 19A:2457-2438, 5'-TCTCTGGATCCCCAGGGTTG-3' and 19A:2569-2549, 5'-GTCAGAATTTTATTTTGGC-20S:2571-2591, 5'-AGGCTATGGAAGGGCTAG-3' and 20A:2750-2731, 5'-CAATCTGACACGACAGTGG-3'. Confimation of K19/JCV T-antigen+ TG mice was accomplished using real-time PCR targeting for the JCV T-antigen just before the mice were euthanized.

Observational findings. The observational finding between TG mice and control mice included epilation. All of the 15 TG mice sporadically lost ~50% of their body hair, while 8 control mice lost no hair and 2 control mice had minimally sporadic hair loss. There was no statistical difference in body weight between the TG (26.7±1.10 g) and control mice (27.0±1.05 g). Confirmation of K19/JCV T-antigen+ TG mice was accomplished using real-time PCR targeting for the JCV T-antigen just before the mice were euthanized.

Histologic and IHC findings. Two pulmonary tumors were identified in the TG mice (13.3% of TG mice), while no tumors were found in any other organs examined including the esophagus, stomach, small intestine, large intestine, heart, liver, pancreas, kidney, spleen and brain. One pulmonary tumor occupied over half of the left lung without pulmonary metastasis in a male TG mouse. Histologically, there was a clear boundary between the tumor and normal lung tissue and a small tubular, solid arrangement consisting of irregular and atypical nuclear cells (Fig. 1A and C). Some of the tumor cells morphologically resembled hyperplastic bronchial cells (Fig. 1D). Another pulmonary small tumor without pulmonary metastasis was found in the left lung of a female TG mouse. The histologic examination of this tumor showed a clear boundary between the tumor and normal lung tissue and a small, tubular arrangement consisting of round-to-oval-shaped and mildly atypical nuclear cells (Fig. 1B). Bronchial hyperplasia was more prominent in TG mice than in control mice (Fig. 2A). Some bronchial hyperplasia morphologically resembled a pulmonary tumor, but was characterized as bronchial hyperplasia due to the small size and mild atypia (Fig. 2B). There was a clear tendency toward sporadic aggregation of lymphocytes in the TG mice (Fig. 2C), some of which showed monotone features and mild atypia (Fig. 2D). This finding was not observed in the control mice.
IHC revealed that the pulmonary tumors were positive for JCV T-antigen primarily in the nuclei (Fig. 3A), p53 was also noted primarily in the nuclei (Fig. 3B), with membranous β-catenin (Fig. 3C) and cytoplasmic CK-19 (Fig. 3D). Insulin receptor substrate-1 (IRS-1), used as an alternate for insulin-like growth factor receptor (IGFR), was negative as determined by IHC. Tumor cells were CK7(+) and CK20(-). Similar IHC findings were noted in the bronchial epithelium. As shown in Fig. 4A, positivity for JCV T-antigen was noted in the bronchial epithelium.

Scattered aggregations of lymphocytes as shown in Fig. 2C were usually positive for the JCV T-antigen (Fig. 4B) and p53. However, lymphocytes demonstrated polyclonal immunohistochemical reactivity. Some lymphocytes represented T lymphocyte clones, and were positive for CD3 and CD5, as well as balanced CD4 and CD8 positivity. Other lymphocytes represented B lymphocyte clones, and were positive for CD20 and CD79a and, to a lesser degree, CD10. Fig. 4C illustrates CD3(+) lymphocytes and Fig. 4D illustrates CD79a(+) lymphocytes.
Mutation analyses of K-ras and EGFR. No mutations in K-ras were observed. An EGFR mutation was detected in the in-frame exon 19 deletion that eliminates the 5 amino acids glucine-leucine-arginine-glucose-alanine ELREA (del E841-A845). No abnormalities were detected in the corresponding normal benign lung tissue (Fig. 5).

Discussion

This is the first report showing that JCV may be associated with epithelial tumorigenesis in experimental animals. The possibility that spontaneous pulmonary tumors should arise in TG mice is very low in this case, as the back strain of this TG mouse, C57BL/6J, is almost completely resistant to spontaneous pulmonary tumors (19). We did not detect any tumors in other organs; most notably no tumors were detected in the brain. We also did not detect any intra-pulmonary or distant metastasis.

Conventional mouse models for pulmonary cancer almost exclusively give rise to solid, papillary or bronchiolo-alveolar adenocarcinomas. These single or mixed tumor types retain marker expression profiles characteristic for both type II
alveolar as well as Clara cells, and therefore both cell types can serve as hypothetical cells of origin for mouse non-small cell lung cancer (19). Similar experiments demonstrated that mice expressing SV40 large T-antigen from the Clara cell-specific CC10 promoter or alveolar type II cell-specific promoter developed early multifocal bronchial alveolar hyperplasia followed by mixed solid and papillary adenocarcinomas to which the mice succumbed by 4-5 months of age (20-22). Ectopic expression of the HPV-16 E6/E7 transgene under the control of the keratine-5 promoter resulted in lung adenocarcinoma after ~6 months of age (23).

The JCV T-antigen can trigger progression of the cell cycle into the S phase in host cells (3,24) and interacts with p53, resulting in interference with p53 (25) and allowing additional genetic damage, representing a step forward in tumorigenesis (26,27). In the present study, p53 was expressed exclusively in pulmonary tumors and bronchial epithelium. Although we could not determine whether this p53 was wild-type or the mutated type, we hypothesized that p53 may be linked to pulmonary tumorigenesis induced by the JCV T-antigen. The JCV T-antigen can also interact with IRS-1, a major protein of the insulin-like growth factor I receptor (IGF-IR) signaling pathway, which is activated and translocated to the nucleus in the presence of the JCV T-antigen (28). Activated IRS-1 is an adaptor in the cell response to insulin, activating phosphatidylinositol 3-kinase (PI3K), which is implicated in cell survival (29) and proliferation signals (30). The JCV T-antigen can also inhibit homologous recombination-directed DNA repair (HRR) causing DNA damage, mechanistically by its interaction with IRS-1 (31), which also interacts with Rad51 at locations of damaged DNA (32), and thus may contribute to the generation of genetic instability in cells containing JCV (33). In this study, expression of IRS-1 was not found in any type of cells, and therefore we could not find evidence of this mechanism.

The JCV T-antigen also contributes to the stabilization of β-catenin by a novel mechanism mediated by the small GTPase Rac1 (34). β-catenin is an integral component of the Wnt signaling pathway, and stabilization of β-catenin is associated with increased transcription of genes that regulate cellular proliferation, e.g., c-myc and cyclin D1 (8). In our study, expression of β-catenin was restricted to the membrane of tumors and bronchial epithelial cells, but was not expressed in the cytoplasm or nucleus, which led us to hypothesize that expression of β-catenin merely played the role of an adhesion molecule in these cells.

Another mechanism by which JCV may contribute to pulmonary tumorigenesis is similar in some aspects to the role of human papilloma virus (HPV) in cervical carcinoma (35). Viral DNA integration has been only partially addressed in cervical cancer associated with HPV (36). The chromosomal locations of HPV viral integration sites coincide with those of fragile chromosome sites (37) and translocation break-points which have been already detected in other types of carcinomas (38). If the JCV infection is persistent, then there is a high probability that JCV DNA may integrate into the host cell genome, while some of the viral DNA remains similarly to what occurs with HPV in cervical carcinoma (37).

In mouse models of chemical pulmonary tumorigenesis, in which the type of tumor is adenoma or adenocarcinoma, K-ras mutations are frequently observed, whereas genetic alteration of EGF receptor is generally rare (38). In the present study, only one case of bronchial epithelial hyperplasia was examined. In this case, an EGF receptor mutation was detected, while a K-ras mutation was not detected. While it is unclear how mutations of EGF receptor and other molecular alterations are related to the mechanisms involved in pulmonary tumorigenesis in mice, both genetic and epigenetic factors are known to be important for tumorigenesis (39). In this case, it is impossible to resolve the mechanism of the phenomenon based on only one tumor.

Figure 5. Detection of a 15-bp deletion in exon 19 of the EGFR gene in a tumor. (A) Electropherograms of the sequencing (bottom strand) of lung tissues. Underlined sequence in the normal benign lung tissue was deleted in the tumor at the position indicated by an arrowhead. (B) Translation of the sequence around the deletion showing an in-frame deletion of the amino acids ELREA. NM_207655, EGFR mRNA sequence in Genebank for the reference. EGFR, epidermal growth factor receptor.
In this study, we found that some lymphocytes were positive for both the JCV T-antigen and p53 in the nuclei. However, these lymphocytes were not found to be monoclonal by IHC. The hypothesis suggesting that lymphocytes mediate JCV infection was reported in a previous study (40). Lymphocytes may have tolerance for JCV activation, leading to positivity for both JCV T-antigen and p53.

Acknowledgements

This study was partially supported by a Grant-in-Aid for Scientific Research (nos. 221S0001 and 23659958) from the Ministry of Education, Science, Sports and Culture, Japan.

References

1. Coelho TR, Almeida L and Lazo PA: JC virus in the pathogenesis of colorectal cancer, an etiological agent or another component in a multistep process. Viril J 7: 42, 2010.
2. Jiang M, Abend JR, Johnson SF and Imperiale MJ: The role of polyomaviruses in human disease. Viril 384: 266-273, 2009.
3. Khalili K, Sariyer IK and Safak M: Small tumor antigen of polyomavirus role in viral life cycle and cell transformation. J Cell Physiol 215: 309-319, 2008.
4. Nagy G, Walker DL, Padgett BL, ZuRhein GM, Kutsuna T, Zheng H, Abdel-Aziz HO, Murai Y, Zheng HC, Abdel Aziz HO, Hori R, Murai Y, Tsuneyama K, Enam S, Del Valle L, Lara C, Laghi L, Randolph AE, Chauhan DP, Del Valle L, White MK and Khalili K: Potential mechanisms of polyomavirus JC, early protein. J Cell Biochem 67: 521-531, 1998.
5. Jiang M, Abend JR, Johnson SF and Imperiale MJ: The role of polyomaviruses in human disease. Viril 384: 266-273, 2009.
6. Khalili K, Del Valle L, Otte J, et al: Human neurotropic polyomavirus, JCV, and its role in carcinogenesis. Oncogene 22: 5181-5191, 2003.
7. Del Valle L, White MK and Khalili K: Potential mechanisms of the human polyomavirus JC in neural oncosogenesis. J Neurpathol Exp Neurrol 67: 729-740, 2008.
8. Laghi L, Randolph AE, Chauhan DP, et al: JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc Natl Acad Sci USA 96: 7484-7489, 1999.
9. Enam S, Del Valle L, Lara C, et al: Association of human polyomavirus JC with colon cancer: evidence for interaction of viral T-antigen and β-catenin. Cancer Res 62: 7093-7101, 2002.
10. Hori R, Murai Y, Tsuneyama K, et al: Detection of JC virus DNA sequences in colorectal cancers in Japan. Virchows Arch 447: 72-81, 2005.
11. Murai Y, Zheng HC, Abdel Aziz HO, et al: High JC virus load in gastric cancer and adjacent non-cancerous mucosa. Cancer Sci 98: 25-31, 2007.
12. Katsunia T, Zheng H, Abdel-Aziz HO, et al: High JC virus load in tongue carcinomas may be a risk factor for tongue tumorigenesis. Virchows Arch 452: 405-410, 2008.
13. Zheng H, Abdel Aziz HO, Nakanishi Y, et al: Oncogenic role of JC virus in lung cancer. J Pathol 212: 306-315, 2007.
14. Walker DL, Padgett BL, ZuRhein GM, et al: Human papovavirus (JC): induction of brain tumors in hamsters. Science 181: 674-676, 1973.
15. Krynska B, Otto J, Franks R, et al: Human ubiquitous JCV(CY) T-antigen gene induces brain tumors in experimental animals. Oncogene 18: 39-46, 1999.
16. Shollar D, Del Valle L, Khalili K, et al: JCV T-antigen interacts with the neurofibromatosis type 2 gene product in a transgenic mouse model of malignant peripheral nerve sheath tumors. Oncogene 23: 5459-5467, 2004.
17. Elphick GF, Querbes W, Jordan JA, et al: The human polyomavirus, JCV, uses serotomin receptors to infect cells. Science 306: 1380-1383, 2004.
18. Oshima H, Matsunaga A, Fujimura T, et al: Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology 131: 1086-1095, 2006.
19. Kawachi H, Obata M, Ogawa K and Lee GH: Roles of the Ras1 and Par2 genes in determination of the unique, intermediate susceptibility of BALB/cByJ mice to urethane-induction of lung carcinogenesis: differential effects on tumor multiplicity, size and Kras2 mutations. Oncogene 15: 1833-1840, 1997.
20. Meuwissen R and Berns A: Mouse models for human lung cancer. Genes Dev 19: 643-664, 2005.
21. DeMayo FJ, Finegold MJ, Hansen TN, et al: Expression of SV40 T-antigen under control of rabbit uteroglobin promoter in transgenic mice. Am J Physiol 261: L70-L76, 1991.
22. Wikenheiser KA, Clark JC, Linnoila RI, et al: Simian virus 40 large T-antigen directed by transcriptional elements of the human surfactant protein C gene produces pulmonary adenocarcinomas in transgenic mice. Cancer Res 52: 5342-5352, 1992.
23. Sandmüller A, Halter R, Gómez-Merino X, et al: The urothelain promoter targets expression of the SV40 T antigen to a variety of secretory epithelial cells in transgenic mice. Oncogene 9: 2085-2095, 1994.
24. Carraresi L, Tripodi SA, Mulder LC, et al: Thymic hyperplasia and lung carcinomas in a line of mice transgenic for keratin 5-driven HPV16 E6/E7 oncoproteins. Oncogene 20: 8148-8153, 2001.
25. Krynska B, Gordon J, Otte J, et al: Role of cell cycle regulators in tumor formation in transgenic mice expressing the human neurotropic virus, JCV, early protein. J Cell Biochem 67: 223-230, 1997.
26. Staib C, Pesch J, Gerwig R, et al: p53 inhibits JC virus DNA replication in vivo and interacts with JC virus large T-antigen. Virology 219: 237-246, 1996.
27. Niv Y, Goel A and Boland CR: JC virus and colorectal cancer: a possible trigger in the chromosomal instability pathways. Curr Opin Gastroenterol 21: 85-89, 2005.
28. Nosho K, Shimba K, Kure S, et al: JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. Oncotarget 11: 87-95, 2019.
29. Khalili K, Del Valle L, Wang JY, et al: T-antigen of human polyomavirus JC cooperates with IGF-IR signaling system in cerebellar tumors of the childhood-medulloblastomas. Anticancer Res 23: 2035-2041, 2003.
30. del Rincon SV, Rousseau C, Samanta R and Miller WH Jr: Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI3-kinase/AKT pathway. Oncogene 22: 3353-3360, 2003.
31. Dearth RK, Xu C, Kim HK, et al: Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 6: 705-713, 2007.
32. Yu Y and Alwine JC: Interaction between simian virus 40 large T antigen and insulin receptor substrate 1 is disrupted by the K1 mutation, resulting in the loss of large T antigen-mediated phosphorylation of Akt. J Virol 82: 4521-4526, 2008.
33. Trojaneck J, Croul S, Ho L, et al: T-antigen of the human polyomavirus JC attenuates faithful DNA repair by forcing nuclear interaction between IRS-1 and Rad51. J Cell Physiol 206: 35-46, 2006.
34. Reiss K, Khalili K, Giordano A and Trojanek J: JC virus large T-antigen and IGF-I signaling system merge to affect DNA repair and genomic integrity. J Cell Physiol 206: 295-300, 2006.
35. Bhattacharyya R, Noch EK and Khalili K: A novel role of Rac GTase in JCV T-antigen-mediated β-catenin stabilization. Oncogene 26: 7628-7636, 2007.
36. Lazo PA: The molecular genetics of cervical carcinoma. Br J Cancer 80: 2008-2018, 1999.
37. zur Hausen H: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92: 690-698, 2000.
38. Pescue NC and DiPaolo JA: Preferential sites for viral integration on mammalian genome. Cancer Genet Cytoenet 42: 157-171, 1989.
39. Lazo PA, Gallego MI, Ballester S and Feduchi E: Genetic alterations by human papillomaviruses in oncogenesis. FEBS Lett 300: 109-113, 1992.
40. Yamakawa K, Kuno T, Hashimoto N, et al: Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 72: 9918-9923, 1998.